Dr. Constantine S. Tam presents 5-year follow-up results from the SEQUOIA trial, showing that frontline zanubrutinib provides durable progression-free and overall survival with a consistent safety profile in patients with treatment-naïve CLL/SLL, including those with del(17p). Funding supported by BeOne Medicines USA, Inc. Content independently developed by OncLive.
Hematologic oncology experts share the studies they were most excited to see presented at the 2025 EHA Congress.
Miguel Gonzalez-Velez, MD, discusses the clinical implications of several lung cancer trials that were presented at the 2025 ASCO Annual Meeting.
Adjuvant nivolumab generated durable DFS and DMFS outcomes in resectable esophageal or GEJ cancer.
TTFields plus chemotherapy improved overall survival in unresectable, locally advanced pancreatic ductal adenocarcinoma.
Adjuvant atezolizumab plus mFOLFOX6 improved disease-free survival vs mFOLFOX6 alone in patients with stage III, mismatch repair–deficient colon cancer.
Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.
Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.
The addition of durvalumab to perioperative FLOT improved event-free survival in resectable gastric/GEJ adenocarcinoma.
The top 5 OncLive videos of the week cover insights in non–small cell lung cancer, small cell lung cancer, and breast cancer.
A post hoc analysis of NAPOLI-3 reveals insights on long-term survivors with pancreatic cancer who received NALIRIFOX.
